As SH3BGRL was predicted to bind with HER2 [14], we then figured out the exact function of SH3BGRL in HER2-positive breast cancers and revealed that SH3BGRL can efficiently bind with HER2, which subsequently activates the downstream signals to enhance the HER2-targeted drug resistance [15]. Here, SH3BGRL is linked to breast carcinoma.